- Direction
- Unknown
- Own history
- —
- Peers
- 94th
- Persistence
- TRANSIENT
· Surgical & Medical Instruments & Apparatus
RESEARCH SNAPSHOTKESTRA MEDICAL TECHNOLOGIES, LTD.'s latest supported as-filed period reports revenue of $31.0M, 59.9% above the comparable as-filed period; gross margin moved 1081 basis points higher on the same comparison basis. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 26.91% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -104.28% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 59.88% · CORE
Level · gp.fundamentals.gross_margin
Raw value 56.50% · CORE
Level · gp.fundamentals.operating_margin
Raw value -121.59% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 21.94% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 59.9%; Operating margin moved 2749 bp higher; Operating income decreased 30.4%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 59.9%; Operating margin moved 2749 bp higher; Operating income decreased 30.4%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents decreased 65.9%; Operating cash flow decreased 22.9%.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Shares outstanding increased 15.8%; SBC / revenue moved 709 bp higher.
2 evidence-backed componentsOperating income changed -30.4% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
KMTS · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-438722SEC ↗4Oct 29, 2026Period Oct 27, 20260001193125-26-438662SEC ↗4Oct 22, 2026Period Oct 21, 20260001193125-26-428980SEC ↗4Oct 22, 2026Period Oct 20, 20260001193125-26-428976SEC ↗4Oct 1, 2026Period Sep 30, 20260001193125-26-410928SEC ↗4Sep 23, 2026Period Sep 21, 20260001193125-26-399696SEC ↗10-QSep 14, 2026Period Jul 31, 20260001193125-26-390766SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 29, 2026Filed Oct 29, 2026 | Mahboob VaseemChief Financial Officer | Option ExerciseDirect | 4,788 | $0 | $0 | Form 4 ↗ |
| Oct 29, 2026Filed Oct 29, 2026 | Mahboob VaseemChief Financial Officer | Open Market SaleDirect | 4,788 | $31 | $146,503 | Form 4 ↗ |
| Oct 29, 2026Filed Oct 29, 2026 | Mahboob VaseemChief Financial Officer | Option ExerciseDirect | 4,788 | $17 | $81,396 | Form 4 ↗ |
| Oct 28, 2026Filed Oct 29, 2026 | Mahboob VaseemChief Financial Officer | Open Market SaleDirect | 39,903 | $30 | $1.2M | Form 4 ↗ |
| Oct 28, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.sbc_revenue_ratio
Raw value 30.73% · OPTIONAL
Operating margin changed +2749 basis points from the comparable as-filed period.
Gross margin changed +1081 basis points from the comparable as-filed period.
Revenue changed +59.9% from the comparable as-filed period.
Operating cash flow changed -22.9% from the comparable as-filed period.
Free-cash-flow proxy changed -18.0% from the comparable as-filed period.
Research & development changed +69.9% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-07-31. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-390535| Mahboob VaseemChief Financial Officer |
| Option ExerciseDirect |
| 39,903 |
| $17 |
| $678,351 |
| Form 4 ↗ |
| Oct 28, 2026Filed Oct 29, 2026 | Mahboob VaseemChief Financial Officer | Option ExerciseDirect | 39,903 | $0 | $0 | Form 4 ↗ |
| Oct 27, 2026Filed Oct 29, 2026 | Mahboob VaseemChief Financial Officer | Option ExerciseDirect | 34,809 | $17 | $591,753 | Form 4 ↗ |
| Oct 27, 2026Filed Oct 29, 2026 | Mahboob VaseemChief Financial Officer | Option ExerciseDirect | 34,809 | $0 | $0 | Form 4 ↗ |
| Oct 27, 2026Filed Oct 29, 2026 | Mahboob VaseemChief Financial Officer | Open Market SaleDirect | 34,809 | $30 | $1.0M | Form 4 ↗ |
| Oct 21, 2026Filed Oct 22, 2026 | Umberger Traci SSee Remarks | Option ExerciseDirect | 100,000 | $0 | $0 | Form 4 ↗ |
| Oct 21, 2026Filed Oct 22, 2026 | Umberger Traci SSee Remarks | Option ExerciseDirect | 100,000 | $17 | $1.7M | Form 4 ↗ |
| Oct 21, 2026Filed Oct 22, 2026 | Umberger Traci SSee Remarks | Open Market SaleDirect | 96,404 | $27 | $2.6M | Form 4 ↗ |
| Oct 21, 2026Filed Oct 22, 2026 | Umberger Traci SSee Remarks | Open Market SaleDirect | 3,596 | $28 | $101,017 | Form 4 ↗ |
| Sep 30, 2026Filed Oct 1, 2026 | COHEN RAYMOND WDirector | Open Market SaleDirect | 3,330 | $29 | $97,504 | Form 4 ↗ |
| Sep 21, 2026Filed Sep 23, 2026 | Kwo ElizabethDirector | Open Market SaleDirect | 4,010 | $24 | $97,268 | Form 4 ↗ |
| Sep 9, 2026Filed Sep 10, 2026 | Schwartz Jeffrey LawrenceDirector | Grant Or AwardDirect | 7,217 | — | — | Form 4 ↗ |
| Sep 9, 2026Filed Sep 10, 2026 | Kwo ElizabethDirector | Grant Or AwardDirect | 7,217 | — | — | Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 | Schwartz Jeffrey LawrenceDirector | Open Market SaleDirect | 3,890 | $25 | $97,942 | Form 4 ↗ |
| Aug 17, 2026Filed Aug 18, 2026 | Webster Brian DanielSee Remarks | Open Market SaleDirect | 15,000 | $27 | $412,181 | Form 4 ↗ |